Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison of Empaglifozin and Vildagliptin in Efficacy and Safety in Type 2 Diabetes Mellitus

NCT05359432 is registered in ClinicalTrials.gov with Getz Pharma as lead sponsor.

NCT NCT05359432
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05359432 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison of Empaglifozin and Vildagliptin in Efficacy and Safety in Type 2 Diabetes Mellitus
Lead sponsor
Getz Pharma
Phase
Phase 4
Overall status
Completed
Start date
July 1, 2020
Completion date
August 18, 2021
Enrollment
120 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes